financetom
Business
financetom
/
Business
/
Replenish Nutrients Unveils New Product Offering and Licensing Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Replenish Nutrients Unveils New Product Offering and Licensing Deal
Sep 23, 2025 2:10 PM

04:53 PM EDT, 09/23/2025 (MT Newswires) -- Replenish Nutrients Holding ( VVIVF ) on Tuesday said entered into a licensing agreement with MJ Ag Solutions, a Northern Alberta-based fertilizer distributor, to distribute a new proprietary product offering targeted at farmers in northern Alberta.

Under the deal, MJ Ag will serve as a licensed supplier for Replenish's fertilizer products in northern Alberta.

The pellet fertilizer product line incorporates soil-health-enhancing fertilizer blends with MJ Ag's local distribution capabilities and support. The arrangement is expected to help northern Alberta farmers improve soil fertility and increase crop potential.

Replenish noted that the licensing deal comes at a time when demand for regenerative fertilizer solutions is growing and when its production facilities, including its Beiseker, Alberta, facility are being scaled up to meet higher sales volume.

"We believe this agreement marks an exciting milestone for Replenish and a strong validation of our licensing model. By partnering with MJ Ag Solutions Ltd., we are positioned to generate a new, recurring revenue stream that requires no additional shareholder capital. The potential to replicate this structure not only across North America but also in other markets gives us what we view as a compelling long-term growth opportunity," chief executive Neil Wiens said,

Shares of Replenish Nutrients ( VVIVF ) closed unchanged at $0.075 on the Canadian Securities Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved